Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate in active axial spondyloarthritis and ankylosing spondylitis
ChiCTR-IPR-15006753Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methotrexate in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) (8 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Clinical improvement assessed by ASDAS. Planned start Aug 2014; status: not yet recruiting.
02
Drugs
methotrexate
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on ChiCTR-IPR-15006753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006753.